Download presentation
Presentation is loading. Please wait.
Published byΛήδα Ουζουνίδης Modified over 6 years ago
1
Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
Andreas Wollenberg, MD, Michael D. Howell, PhD, Emma Guttman-Yassky, MD, PhD, Jonathan I. Silverberg, MD, PhD, MPH, Christopher Kell, PhD, Koustubh Ranade, PhD, Rachel Moate, MSc, René van der Merwe, MBBS Journal of Allergy and Clinical Immunology DOI: /j.jaci Copyright © 2018 The Authors Terms and Conditions
2
Fig 1 A-C, Adjusted mean change in EASI score from baseline over time for the ITT population (Fig 1, A∗), DPP-4-high subgroup (Fig 1, B†), and periostin-high subgroup (Fig 1, C‡). D-F, Adjusted percentage of participants with an IGA response at week 12 for the ITT population (Fig 1, D∗), DPP-4-high subgroup (Fig 1, E†), and periostin-high subgroup (Fig 1, F‡). Participants were considered IGA responders if they had an IGA response of 0 or 1 and a reduction of 2 grades or more from baseline to week 12. IGA severity categories are as follows: 0, clear; 1, almost clear; 2, mild; 3, moderate; 4, severe; and 5, very severe. ∗Participants randomized to treatment: placebo, n = 51; tralokinumab 45 mg, n = 50; tralokinumab 150 mg, n = 51; tralokinumab 300 mg, n = 52. †Participants randomized to treatment: placebo, n = 24; tralokinumab 45 mg, n = 25; tralokinumab 150 mg, n = 23; tralokinumab 300 mg, n = 30. ‡Participants randomized to treatment: placebo, n = 25; tralokinumab 45 mg, n = 24; tralokinumab 150 mg, n = 25; tralokinumab 300 mg, n = 28. Journal of Allergy and Clinical Immunology DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions
3
Fig 2 Adjusted percentage of participants achieving a reduction of 50% or more (EASI50) and 75% or more (EASI75) in EASI score (A) and 50% or more in SCORAD score (SCORAD50; B) at week 12. Analyses were last observation carried forward, excluding data from participants who took prohibited medications. Journal of Allergy and Clinical Immunology DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions
4
Fig 3 Adjusted mean change from baseline in SCORAD score (A), pruritus numeric rating scale (NRS) score (B), and Dermatology Life Quality Index (DLQI) score (C) for the ITT population. Journal of Allergy and Clinical Immunology DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions
5
Fig E1 Journal of Allergy and Clinical Immunology DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions
6
Fig E2 Journal of Allergy and Clinical Immunology DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.